News and Events

You are here

Rituximab/MabThera Questionnaire

Posted on Monday, 7 May 2018

The drug Rituximab, otherwise known as MabThera, appears to be a more regularly considered treatment option for people with Myasthenia Gravis.

Access to this drug varies greatly depending on each individual situation.

The Myasthenia Alliance Australia Committee is interested in learning more about accessing difficulties Australians are facing.

We ask that anyone in Australia who has been offered, or is currently receiving this drug treatment, please complete this questionnaire. Your urgent response is needed.

The questionnaire can be found on page 2 of the MGAQ April Newsletter or visit to download the questionnaire.